Cornea

Offer options to your cataract patientsAs primary-care optometrists, we are the gatekeepers for baby boomers inquiring about cataract surgery. Today’s patients have treatment options available not only to address their lifestyle complaints but to provide them with better vision and possibly reduced dependence on glasses or contact lenses.
Haze after PRK, LASIK tied to faulty epithelial regrowth
Haze after PRK, LASIK tied to faulty epithelial regrowthPoor regeneration of the epithelial basement accounts for most 'late haze' associated with PRK, LASIK, infections, or corneal transplants. Proper excimer laser maintenance may reduce irregularities.
The utility of normal tear osmolarity results
The utility of normal tear osmolarity resultsPatient symptoms are not an effective method to diagnose dry eye, as they often overlap with other pathologies. Tear osmolarity results provide clues for alternative diagnoses.
Lifitegrast data support dry eye efficacy over placebo dropsLifitegrast ophthalmic solution 0.05% (Xiidra, Shire) has demonstrated positive results for the treatment of the signs and symptoms of dry eye disease. Eye dryness scores for some patients have improved after two weeks of treatment with the topical drop.
Protein agent may change approach to treating dry eye, inflammationRecombinant human lubricin showed potential as a new therapeutic approach to the management of dry eye disease in a small clinical trial. Compared with sodium hyaluronate, lubricin (Lubris BioPharma), significantly improved both signs and symptoms of moderate dry eye after two weeks of treatment.
Exploring off-label, investigational approaches for allergic conjunctivitisSeasonal and perennial allergic conjunctivitis are common conditions that are not always well-controlled with conventional therapy. Alternative approaches and novel investigational treatments are discussed.
Novel topical peptide for dry eye tackles underlying cause of diseaseA phase I/II trial enrolling patients with Sjögrens syndrome dry eye will be investigating  a synthetic fragment of a naturally occurring tear glycoprotein. Findings from extensive laboratory and preclinical research suggest that it is a promising novel therapy.
Novel neurostimulator device uses nasal cavities to stimulate tearsChronic dry eye disease (DED) affects more than 25 million people and to date the only pharmacologic therapies are topical or involve punctal plugs. Results from two studies wth a neurostimulator indicate there may be a new pathway to upregulate the body’s tear system.
No sign of chloramphenicol resistance in bacterial conjunctivitisChloramphenicol remains effective against Gram-positive bacteria, the most common agent in bacterial conjunctivitis, researchers say.
Clinicians coming to terms with dysfunctional lens syndromeUsing dysfunctional lens syndrome stages, physicians can discuss a range of treatment options with patients, based on clinical findings and refractive error.